Nutritional science for mind health products
DSM Nutritional Products
In a statement the firm said it will carry out a series of trials on its m.doc technology in combination with another cholesterol-lowering ingredient, plant sterols, and the popular fatty acid, omega-3.
The aim is to test for any synergistic benefit from combining m-doc with another ingredient.
A number of ingredient makers and food companies are backing the trials, with pre-clinicals beginning mid January, and the government body Enterprise Ireland has also pledged its support.
Prior trials on the dose-dependent efficacy of the m.doc technology platform confirmed cholesterol-lowering effects in line with commercially available sterol products. The cellulose particles have also been shown to lower LDL cholesterol levels in animal studies.
Alltracel chief executive Tony Richardson said the firm is "accelerating discussions to commercialise the technology with a number of multinational partners in 2006".
It has had strong interest from Asia but is also in talks with European and US companies.
The first research on the anti-atherosclerosis benefits was published in the November issue of the Life Sciences Journal. Further scientific publications are set to follow in 2006, said Alltracel.